Format

Send to

Choose Destination
J Turk Ger Gynecol Assoc. 2019 Feb 26;20(1):31-36. doi: 10.4274/jtgga.galenos.2018.2018.0015. Epub 2018 Mar 16.

In patients with advanced ovarian cancer, primary suboptimal surgery has better survival outcome than interval suboptimal surgery

Author information

1
Clinic of Gynecologic Oncology, İstanbul Training and Research Hospital, İstanbul, Turkey
2
epartment of Gynecologic Oncology, İstanbul University İstanbul School of Medicine, İstanbul, Turkey

Abstract

Objective:

It is known that optimal or complete cytoreduction is the most important factor in patients with advanced ovarian cancer. The aim of this study was to examine the results of patients who did not undergo optimal cytoreduction and to examine subgroup analysis based on neoadjuvant chemotherapy (NAC).

Material and Methods:

Patients with advanced ovarian cancer and suboptimal surgery were retrospectively reviewed.

Results:

A total of 99 patients with a median age of 59.0 years (range, 22-87 years) were studied. The median follow-up time was 39±32.7 months, 81 patients (81.8%) died and 18 patients (18.2%) were alive. The five-year survival rate was 27.6%. Of the patients, 37 (37.4%) were underwent surgery after NAC, 62 (62.3%) were primary. More patients with NAC died within 3 years compared with those without NAC (83.9% vs 56.0%) (p=0.015). Patients with NAC had less tumor spread (presence of visible tumor in the upper abdomen during surgery) (29.7% vs 72.6%; p<0.001) and had less overall survival times when compared with patients who underwent primary surgery [median 22.3±1.2; 95% CI: (19.9-24.7) vs (37.5±11.2); 95% CI: (15.4-59.5) months; log rank test p=0.055]. The relationship between overall survival and factors such as age, NAC, presence of metastasis in the upper abdomen, and tumor histology (serous vs. non-serous) were analyzed using univariate cox regression analysis. Of these factors, only NAC was close to significant, but it did not reach significance (p=0.055).

Conclusion:

NAC reduces tumor burden before surgery in advanced ovarian cancer. The prognosis of patients who are not eligible for optimal surgery despite NAC is worse than in patients who do not receive NAC.

KEYWORDS:

neoadjuvant chemotherapy; Primary surgery; cytoreductive surgery; survival

Free full text

Supplemental Content

Full text links

Icon for Galenos Yayinevi
Loading ...
Support Center